These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37950531)

  • 21. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.
    Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS).
    Shi X; Cheng Q; Zhao YZ; Zou SP; Sun MH
    Osteoporos Int; 2023 Dec; 34(12):2047-2058. PubMed ID: 37594595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system.
    Shu Y; He X; Wu P; Liu Y; Ding Y; Zhang Q
    Front Public Health; 2022; 10():996179. PubMed ID: 36339230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Major cardiovascular events increase in long-term proprotein convertase subtilisin/kexin type 9 inhibitors therapy: the Tuscany cost-effective study.
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Corciulo C; Lo Surdo G; Biagini S; Sampietro T;
    J Cardiovasc Med (Hagerstown); 2023 Nov; 24(11):808-814. PubMed ID: 37773882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
    Shu Y; Ding Y; Dai B; Zhang Q
    Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab.
    Chen Z; Li M; Li S; Li Y; Wu J; Qiu K; Yu X; Huang L; Chen G
    Expert Opin Drug Saf; 2023 Apr; 22(4):339-342. PubMed ID: 36178002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database.
    Zhou C; Peng S; Lin A; Jiang A; Peng Y; Gu T; Liu Z; Cheng Q; Zhang J; Luo P
    EClinicalMedicine; 2023 May; 59():101967. PubMed ID: 37131541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database.
    Zhao D; Zhang W; Liu Y; Yan Z
    Front Pharmacol; 2024; 15():1389814. PubMed ID: 38783948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data.
    Zhang Q; Ding Y; Shu Y; Chen J
    BMC Cancer; 2023 Aug; 23(1):745. PubMed ID: 37568126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
    Kong W; Mao W; Zhang L; Wu Y
    Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurological and Psychiatric Adverse Events Associated with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer Patients: Insights from a Pharmacovigilance Study via the FDA Adverse Event Reporting System.
    Yu Z; Guan M; Liao X
    Clin Drug Investig; 2024 Oct; 44(10):789-798. PubMed ID: 39392584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.
    Wu T; Zhang Y; Shi Y; Yu K; Zhao M; Liu S; Zhao Z
    Clin Drug Investig; 2022 Nov; 42(11):965-975. PubMed ID: 36175609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022.
    Wang Y; Cui C; Deng L; Wang L; Ren X
    Front Immunol; 2023; 14():1127128. PubMed ID: 37292205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.
    Zhang S; Wang Y; Qi Z; Tong S; Zhu D
    Int J Clin Pharm; 2024 Apr; 46(2):471-479. PubMed ID: 38245664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021.
    Wang Y; Cui C; Ren X; Dong X; Cui W
    Front Cardiovasc Med; 2022; 9():988013. PubMed ID: 36312283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database.
    di Mauro G; Zinzi A; Scavone C; Mascolo A; Gaio M; Sportiello L; Ferrajolo C; Rafaniello C; Rossi F; Capuano A
    Drug Saf; 2021 Mar; 44(3):337-349. PubMed ID: 33351170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databases.
    Zou S; Ouyang M; Zhao Y; Cheng Q; Shi X; Sun M
    Front Pharmacol; 2024; 15():1392914. PubMed ID: 39027335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS.
    Chai S; Zhan JL; Zhao LM; Liu XD
    Ther Adv Drug Saf; 2022; 13():20420986221143266. PubMed ID: 36545565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
    Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
    Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.